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Abstract 
Obesity continues to be a growing issue in the United States with an estimated prevalence 
of 72 million people. There are major health implications associated with obesity including 
its relationship with hypertension, diabetes mellitus type 2, the metabolic syndrome, and 
dyslipidemia, all independent risk factors for CAD. Despite the increased risk of developing 
CAD, in recent years an “obesity paradox” has been described in which moderately obese 
individuals with established cardiovascular disease, including CAD, appear to have 
mortality similar to their normal weight counterparts. This review discusses the 
relationship between obesity and CAD, including the increased risk of hypertension, 
diabetes mellitus, the metabolic syndrome, and dyslipidemia along with a discussion of the 
obesity paradox and the benefits of weight reduction. 
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Abbreviations 
BF: Body fat 
BMI: Body mass index 
CABG: Coronary artery bypass graft 
CAD: Coronary artery disease 
CI: Confidence interval 
COPD: Chronic obstructive pulmonary disease 
CV: Cardiovascular 
CVD: Cardiovascular disease 
DM: Diabetes mellitus 
ESRD: End stage renal disease 
HDL-C: High density lipid cholesterol 
HTN: Hypertension 
IRO: Insulin- resistant obese 
LDL-C: Low density lipid cholesterol 
LMI: Lean mass index 
MetS: Metabolic syndrome 
MHO: Metabolically healthy obese 
MI: Myocardial infarction 
PCI: Percutaneous coronary intervention 
RR: Relative risk 
STEMI: ST elevation myocardial infarction 
TG: Triglycerides  
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Introduction 
Obesity, defined as a body mass index (BMI) ≥30 kg/m2, constitutes a major problem in the 
United States (US) with an overall prevalence estimated at 72 million people.(1, 2) Due to 
the numerous health implications associated with obesity, it is currently estimated to be 
the second leading caused of preventable death.(2, 3) Obesity is associated with increased 
risk of hypertension (HTN), diabetes mellitus type 2 (DM), the metabolic syndrome (MetS), 
and dyslipidemia, all risk factors for coronary artery disease (CAD).(4, 5) Obesity, however, 
is not homogeneous in its effect, with a subset of obese individuals that are relatively 
insulin sensitive, labeled metabolically healthy obese (MHO), who have a more favorable 
cardiovascular (CV) profile compared to insulin-resistant obese (IRO) individuals.(6-11) 
The relationship between obesity and CAD is further complicated by the idea of the 
“obesity paradox” where mildly obese individuals have similar or lower mortality to their 
normal weight counterparts. This review discusses the relationship of obesity and CAD, 
including the possible mechanisms through which obesity increases CAD risk, the MHO 
individuals, along with a discussion of the “obesity paradox” in CAD and its implications in 
patient management including weight loss. 
 
Obesity and its association with CAD risk factors 
Obesity is associated with increased risk of HTN, DM, MetS, and dyslipidemia.(4, 5) 
Through its affect on these diseases, obesity increases the risk of developing CAD. In the 
following section we describe the relationship between obesity and CAD. 
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Obesity’s relationship with HTN has been well described in the literature in large studies 
such as the Framingham cohort and the Physician’s Health Study.(12-14) The Framingham 
cohort demonstrated that 34% of HTN in men and 62% of HTN in women aged 35-75 years 
was attributable to excess weight (defined as a BMI ≥25 kg/m2).(12) The Physician’s Health 
Study described an 8% increase in risk of incident HTN with each 1-unit increase in BMI 
during a median follow-up of 14.5 years.(13) Weight loss, on the other hand, decreases the 
risk of HTN. An analysis of the Framingham cohort demonstrated that sustained weight 
loss of 1.8 kg or more was associated with a long term HTN risk reduction of 22% in 
middle-aged patients and a 26% reduction in older patients.(14) The mechanism for the 
association between obesity and HTN is likely multifactorial. (Table 1) Through the 
production of angiotensin, a precursor of the renin-angiotensin-aldosterone system, 
adipose cells have a endocrine effect on a known pathway for the pathogenesis of HTN.(15) 
Beyond adipose cell’s endocrine effect, there is an increase in circulating blood volume and 
total peripheral resistance seen with increasing BMI, which may lead to HTN.(16)  
 
Obesity is an independent risk factor for both DM and MetS, with the prevalence of DM 
being closely related to the rise in obesity.(17, 18) The Behavioral Risk Factor Surveillance 
System demonstrated that the prevalence of DM increased 33% throughout follow up, a 
rise related with increasing rates of obesity.(18) DM increases the risk of CAD through its 
association with endothelial dysfunction and dyslipidemias, both initial steps in the 
atherogenic process. (Table 1) Through these mechanisms, DM is one of the strongest CAD 
risk factors, characterized by very high 10-year risk of CV events.(15, 19)  Additionally, DM 
is a common cause of renal dysfunction, an independent risk factor for CAD.(15) Similarly 
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MetS increases the risk of CAD and is defined by HTN, dyslipidemia, impaired fasting 
glucose, and central obesity, all risk factors for CAD.(20-24) 
 
The exact mechanisms linking obesity with insulin resistance and other factors influencing 
risk of DM and CAD are unclear.(5) (Table 1) Research shows that adipose tissue functions 
as an endocrine organ and has been associated with elevated levels of circulating 
proinflammatory cytokines and fat related hormones.(22, 25, 26) A number of 
inflammatory responses are found to occur with obesity including increased clotting 
factors such as fibrinogen, von Willebrand factor, and factors VII and VIII; and increasing 
plasminogen activator inhibitor type-I that are associated with decreased fibrinolysis, all 
which may lead to increasing CAD.(22, 25, 26) Elevated levels of tumor necrosis factor 
alpha in obesity have also been implicated in the development of insulin resistance.(15, 27) 
Finally, leptin levels are higher in obesity and chronically elevated leptin levels have been 
related to negative CAD outcomes and are associated with in-stent restenosis.(28) Other 
potential mechanisms for the increase in CAD risk associated with DM include decreased 
insulin-mediated vasodilation, increased insulin-mediated renal sodium reabsorption, 
insulin related sympathetic nervous system stimulation, and increased vasoconstriction 
related to elevated circulating free fatty acids.(25, 26)  
 
Obesity, in addition to increasing the risk of HTN and DM, also increases the risk for 
dyslipidemia. Higher BMI is associated with lower levels of high-density lipoprotein 
cholesterol (HDL-C), high levels of triglycerides, in addition to small, dense, atherogenic 
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low-density lipoprotein cholesterol (LDL-C), all potentially increasing the risk for CAD.(20, 
21, 29, 30) (Table 1) 
 
The metabolically healthy obese 
Among individuals who are obese, there is a subset of MHO individuals that are relatively 
insulin sensitive and have a more favorable lipid and inflammatory profile compared to IRO 
individuals.(6-11) Those with MHO compared to IRO appear to have earlier onset of 
obesity, fasting plasma insulin levels within normal range, a normal distribution of the 
excess fat, and other family members with MHO.(7, 8) These individuals also appear to 
have less visceral adipose tissue and more favorable lipid profiles including lower plasma 
triglyceride (TG) and higher HDL-C levels then their insulin-resistant counterparts.(8) 
Compared to normal weight counterparts, MHO persons appear to have higher burden of 
subclinical CV Disease (CVD) (31) and markers of CAD (32), while their CV risk profile is 
intermediate between a healthy non-obese individual and someone with IRO.(33) Thus, 
while MHO may increase the risk of CVD, how it impacts CAD is still unclear and further 
research needs to be performed to more fully understand the relationship between MHO 
and CAD. 
 
The obesity paradox 
Despite the increased risk of developing CAD and its risk factors, epidemiologic data from 
recent years has described an “obesity paradox”. The obesity paradox refers to the finding 
that despite an increased risk of developing CVD in the obese, once CVD has been 
established, overweight and mildly obese individuals may have a decreased or similar 
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outcomes and mortality compared to their normal weight counterparts. This paradox has 
been described in a number of CV diseases such as CAD, heart failure, and atrial fibrillation 
(1, 5, 34-43), though conflicting data exists in the literature among certain subgroups of 
CAD individuals.(35, 44, 45) The following is a discussion of the obesity paradox in CAD 
cohorts and its implication. 
 
There are numerous studies describing the obesity paradox in CAD in a variety of cohorts 
including hospitalized registries(46, 47), revascularized populations(48, 49), post-coronary 
artery bypass graft surgery (CABG) programs(50), ambulatory settings(51, 52), and high-
risk patients undergoing stress testing.(53, 54) Das and colleagues demonstrated the 
obesity paradox in a cohort of 50,000 patients with ST-segment elevation myocardial 
infarction (STEMI).(49) They described that individuals with moderate obesity (BMI 
between 30-35 kg/m2) had the lowest mortality compared to other weight groups.(49) 
Similarly, another study of individuals presenting with both STEMI and non-STEMI, found 
that in-hospital, adjusted mortality was lowest amongst those with morbid obesity (BMI 
≥40 kg/m2) when compared to those with a BMI <40 kg/m2.(46)  
 
In post-revascularization patients, those receiving either percutaneous coronary 
intervention (PCI) or CABG, data on the obesity paradox is inconsistent. The Do Tirofiban 
and ReoPro Give Similar Efficacy and Outcomes Trial (TARGET), a study of over 4,800 
individuals designed to compare the use of tirofiban and abciximab in planed PCI with bare 
metal stents, demonstrated that there was no difference in 30-day and 6-month outcomes 
of death and MI among obese and non-obese patients, supporting the obesity paradox.(44) 
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However, among individuals younger than 65 years, those who with a BMI >32 kg/m2 had a 
significantly higher rate of target vessel revascularization at 6 months compared with more 
lean patients.(44) Another study demonstrated that patients who underwent PCI of single 
de novo lesion for stable or unstable angina or inducible ischemia found that a BMI >30 
kg/m2 was an independent predictor of target vessel revascularization and major adverse 
cardiac event (MACE) at 1 year in those receiving BMS but no paclitaxel-eluting stents.(45) 
Finally, a study of 6,068 individuals undergoing CABG developed a propensity model that 
demonstrated that over a 12 year span, mortality was similar between those with a normal 
BMI and those who are moderately obese (BMI between 32 to 36 kg/m2), but higher among 
the morbidly obese patients (BMI ≥36 kg/m2).(55) These studies support that individuals 
with CAD and moderate obesity may have similar outcomes to normal weight individuals, 
but that outcomes worsen among morbidly obese.  
 
This statement is supported by a large systematic review and meta-analysis of 40 cohort 
studies and over 250,000-pooled participants with CAD completed by Romero-Corral and 
colleagues.(35) In their study, they describe that when evaluating all individuals with CAD 
(PCI, MI and CABG), moderately obese individuals (BMI 30-35 kg/m2) and those with 
morbid obesity (≥ 35 kg/m2) had no increased risk for total mortality (relative risk 
(RR)=0.93, 95% confidence interval (CI) 0.85-1.03 and RR= 1.10, 95% CI 0.87-1.41, 
respectively). (Figure 1) However, in regards to CV mortality, while moderately obese 
patients had no increase in CV mortality (RR= 0.97, 95% CI 0.82-1.15) compared to the 
normal weight group, those with severe obesity had the highest risk (RR= 1.88, 95% CI 
1.05-3.34). (Figure 2) When stratified by MI, PCI, or CABG, only obese and severely obese 
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patients in the CABG group had significantly higher total mortality than normal weight 
patients.(35) (Figure 1) This systematic review and meta-analysis by Romero-Corral is 
important in the discussion of obesity and CAD as it demonstrates that obese patients do 
not have a significantly higher risk unless further stratified as moderate obese and morbid 
obesity. Furthermore, only CV mortality is worsened among the severely obese. What was 
not seen was an inverse association between obesity and death in patients with CAD, and 
thus caution should be used in discounting obesity as a risk factor for CAD progression and 
complications. 
 
Potential mechanisms for the obesity paradox 
While the mechanism for the potential protective effect of obesity among those with CAD 
remains unclear, there have been several possibilities proposed.(36, 56-58) (Table 2) It has 
been speculated that before a CVD event, positive caloric balance leading to adiposity may 
result in pathogenic adipose tissue responses that cause metabolic diseases, increasing 
cardiovascular disease risk. Paradoxically, during a time of negative caloric balance, as may 
occur during a CV event, adipose tissue may respond with enhanced function, which may 
improve clinical outcomes.(36, 56)  Additionally, individuals with higher body fat (BF) 
leading to their obesity may have increased muscular strength which has been associated 
with better prognosis and survival in several populations.(57, 58)  
 
Another potential mechanism for the obesity paradox may lie in the treatment and 
management of patients based upon BMI. Patients with a BMI above normal may be more 
likely to be treated with American College of Cardiology (ACC)/American Heart Association 
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(AHA)-recommended medications then normal or lower BMI individuals.(59) Additionally, 
obese patients were also shown in one study to undergo more diagnostic and 
revascularization procedures than patients with low or normal BMI.(59) Thus, obese 
individuals may receive more aggressive treatment such as better medical management 
and more revascularization then their normal weight counterparts, leading to better 
outcomes.(59) Finally, there has been some criticism that the paradox only occurs due to 
the inaccurate nature of using BMI to define obesity.(1, 34, 36, 60-64) Critics argue that a 
more meaningful measure of obesity, as shown by various studies, should be measured via 
waist circumference, waist/hip ratio, or BF.(1, 34, 36, 60-64) 
 
Others have proposed that fitness is more important then obesity in improving mortality 
among CAD patients. Fitness alters the relationship between adiposity and all-cause 
mortality in patients with CAD and only those with low levels of fitness seem to have an 
obesity paradox.(65-67) A study by McAuley et al. described that in a population with CAD 
referred for exercise stress testing, fitness altered the obesity paradox.(66) Overweight and 
obese men with moderate fitness had mortality rates similar to the highly fit normal-
weight reference group.(66) (Figure 3) In fact, in most CV disorders, patients with high 
fitness have lower mortality then those with lower fitness (68-70) and fitness appears to 
improve CV mortality when added to other traditional risk factors.(69) Fitness, also 
appears to predict the development of some of the risk factors for CAD such as HTN, MetS, 
and dyslipidemia.(71) Therefore, using adiposity to assess mortality risk in patients with 
CAD may be misleading unless fitness is considered. (65) These studies are limited by 
confounders such as smoking history, undiagnosed chronic disease, the catabolic effects of 
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illness, or having a shorter duration of follow up than is optimal which may both affect the 
ability to be fit while also affecting CV mortality. Despite the findings of the obesity 
paradox, current data does not support increasing weight among individuals with CAD, but 
appear to indicate that fitness is an important part of preventing obesity.(56, 72-76)  
 
Weight loss and CAD 
While obesity appears to demonstrate improved mortality benefit in those with CAD, there 
is still significant evidence supporting weight loss as a way to reverse CAD risk factors, 
including HTN, DM, and dyslipidemia and potentially reduce mortality.(36, 74, 75, 77-86) 
Weight loss has been associated with marked improvements in arterial pressure and LV 
geometry, potentially improving HTN.(86) Additionally, exercise, a potential tool for weight 
loss, has been associated with increases in cardioprotective HDL-C, increased insulin 
sensitivity, and a decrease in the prevalence of MetS and DM.(78-80)  
 
Weight loss also appears to impact mortality in CAD.(36, 74, 75, 77) Lavie et al 
demonstrated that in a cohort of overweight and obese individuals with CAD who 
underwent cardiac rehabilitation after a CV event, greater weight loss lead to 
improvements in metabolic profiles, exercise capacity and a trend towards lower 
mortality.(36) In a study of 1,500 CAD patients, intentional weight loss produced a lower 
incidence of CAD events over 4-year follow-up.(74) Similar findings have also been 
demonstrated in other studies, including a reduction in all-cause and CV mortality with 
weight loss through cardiac rehabilitation and exercise programs(77) and a decrease in 
major CV events with weight loss, including even in individuals with a BMI < 25 kg/m2.(75) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Despite these findings, others have described increased mortality with weight loss (87) and 
the benefit of weight loss, except among the morbidly obese, is unclear.(1, 88-90) What is 
certain is that fitness is important to improve prognosis among CAD patients (81-83) and, 
therefore, physical activity, exercise training and fitness improvements, with potentially 
accompanying purposeful weight loss, should be incorporated into treatment plans of 
overweight or obese patients with CAD.(84, 85) 
 
Conclusion 
Obesity is related to multiple risk factors of CAD including HTN, DM, MetS, and 
dyslipidemia, while also likely being an independent risk factor for CAD. Through multiple 
pathways including increased angiotensin, circulating blood volume, and total peripheral 
resistance excess weight increases HTN risk. (15, 16) Through changes in insulin 
sensitivity, obesity increases the risk of DM and MetS, which lead to changes in endothelial 
function, increased dyslipidemias, and other inflammatory responses all of which increase 
the risk of CAD.(15, 22, 25-28) Obesity also leads to an unfavorable lipid profile, leading to 
elevated CAD risk. (20, 21, 29, 30)  Despite these findings, a subset of obese individuals 
remains insulin-sensitive, the MHO, and maintain a CAD risk profile that is intermediate 
between a healthy non-obese individual and someone with IRO.(33)  
 
While obesity increases the risk for CAD, it appears that in those with established disease, a 
paradox exists where the moderately obese with CAD appear to have improved mortality 
then those with normal weight. Current standards including weight loss and a physical 
activity and exercise program remain the recommendation as they have been associated 
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with reductions in blood pressure, triglycerides, an increase in insulin sensitivity and 
decrease in HDL-C.(77, 89) Therefore, physical activity as a means to improve fitness and 
health outcomes should be promoted throughout the healthcare system despite BMI.(91)  
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Table 1: Potential mechanisms by which obesity increases coronary artery disease risk factors 
Risk factor Mechanism 
Hypertension Production of angiotensin a precursor of the renin-angiotensin-aldosterone system 
Increase in circulating blood volume 
Increase in total peripheral resistance 
Diabetes mellitus 
& metabolic 
syndrome 
Dietary indiscretion that leads to obesity 
Endocrine activity of adipose tissue: 
Increased clotting factors: Fibrinogen, von Willebrand factor, factors VII and VIII 
Increased plasminogen activator inhibitor type-I 
Increased leptin 
Increased tumor necrosis factor alpha 
Endothelial dysfunction: 
Decreased insulin-mediated vasodilation 
Increased insulin-mediated renal sodium resorption 
Insulin related sympathetic nervous system stimulation 
Increased vasoconstriction related to elevated circulating free fatty acids 
Increased risk of dyslipidemia 
Increased risk of renal dysfunction 
Dyslipidemia Low levels of high-density lipoprotein cholesterol 
High levels of triglycerides 
High levels of low-density lipoprotein cholesterol 
  Elevated total cholesterol 
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Table 2: Potential mechanisms for the obesity paradox in coronary artery disease 
A. Greater metabolic reserves 
B. Less cachexia 
C. Younger presenting age 
D. More aggressive medical therapy 
E. More aggressive diagnostic and revascularization procedures 
F. Increased muscle mass and strength 
G. Possible improved cardiorespiratory fitness despite obesity 
H. Attenuated hormonal response including the renin-angiotensin-aldosterone system 
I. Unmeasured confounders, including selection bias* 
* Selection bias may occur in that obese individuals may develop coronary artery disease (CAD) 
due to weight, whereas the etiology of CAD in lean patients may be different and associated with 
worse prognosis. 
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Figure 1. Unadjusted and adjusted relative risks (RR) for total mortality in patients with 
coronary artery disease by different body mass index (BMI) groups compared to normal 
BMI for all groups together and by myocardial infarction (MI), percutaneous coronary 
intervention (PCI), and coronary artery bypass graft (CABG) subgroups. Reproduced with 
permission from Romero-Corral et al.(35) 
 
Figure 2. Unadjusted and adjusted relative risk (RR) for cardiovascular mortality in 
patients with coronary artery disease by body mass index (BMI) groups compared to 
normal BMI groups. After grouping studies with adjusted risks, obese patients had no 
increased risk and severely obese patients had a significantly higher risk compared to 
normal BMI group. Reproduced with permission from Romero-Corral et al.(35) 
  
Figure 3. 9,563 subjects with known or suspected coronary heart disease stratified by body 
mass index (BMI) category (A), waist circumference (WC), and body fat percent (BF) 
tertiles ((B) and (C) respectively) on all cause mortality. Normal BMI, low WC and low BF in 
the high fitness group were used as reference groups. Hazard ratios (boxes) and 95% 
confidence intervals (error bars represent values) after adjusting for age, baseline 
examination year, physical activity, smoking hyperlipidemia, diabetes and family history of 
cardiovascular disease.  Reproduced with permission from McAuley et al.(65)  
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